SCYL3

SCYL3 (PACE-1) is a pseudokinase that links the actin cytoskeleton and Golgi-associated trafficking machinery to cell migration and neuronal proteostasis (PMID:12651155, PMID:36440258). Although it contains an N-terminal kinase-like domain, biochemical assays show it lacks intrinsic catalytic activity and instead carries associated kinase activity, marking it as a scaffolding pseudokinase (PMID:12651155). SCYL3 localizes to the cytoplasmic face of the Golgi apparatus through its N-terminal myristoylation signal and to lamellipodia via a C-terminal interaction with ezrin (PMID:12651155). Through this same C-terminal region it binds and stabilizes ROCK2, enhancing ROCK2 transactivating activity to drive actin stress fiber and focal adhesion formation; in hepatocellular carcinoma this axis promotes proliferation, migration, and metastasis (PMID:36440258). In vivo, SCYL3 acts redundantly with SCYL1 to sustain motor neuron viability and TDP-43 proteostasis: loss of Scyl3 alone is phenotypically silent but accelerates the motor neuron degeneration, TDP-43 mislocalization, and paralysis caused by Scyl1 deficiency (PMID:29437892). Beyond these findings, the molecular basis by which SCYL3 connects its Golgi and cytoskeletal localizations to TDP-43 proteostasis has not been characterized in the available corpus.

1. 2003 Medium

   Established SCYL3 as a myristoylated, Golgi- and lamellipodia-localized pseudokinase that physically engages the cytoskeletal adaptor ezrin, placing an uncharacterized kinase-like protein at the membrane–cytoskeleton interface.

   Evidence Yeast two-hybrid screen, subcellular localization imaging, and biochemical kinase assays

   PMID:12651155

   Open questions at the time

   • Functional consequence of the ezrin interaction for migration not tested
   • Identity of the associated kinase activity not determined
   • No reciprocal validation of the ezrin binding beyond two-hybrid/imaging
2. 2018 High

   Resolved the in vivo role of SCYL3 by showing it acts redundantly with SCYL1 to maintain motor neuron survival and TDP-43 proteostasis, explaining why single Scyl3 loss is phenotypically silent.

   Evidence Scyl1/Scyl3 double-knockout mouse genetic epistasis with histopathology and TDP-43 immunostaining

   PMID:29437892

   Open questions at the time

   • Molecular mechanism linking SCYL3 to TDP-43 localization unknown
   • Whether the trafficking/cytoskeletal roles underlie the neuronal phenotype unresolved
   • No direct substrate or interaction partner identified in neurons
3. 2021 Low

   Used the yeast ortholog Cex1 to propose a conserved SCYL function in COPI-dependent Golgi trafficking and protein glycosylation, providing a candidate mechanistic context for SCYL3's Golgi localization.

   Evidence Co-IP with COPI coat subunits, localization imaging, and yeast deletion phenotyping (yeast ortholog Cex1)

   PMID:33753324

   Open questions at the time

   • Findings are from a yeast ortholog and not validated for mammalian SCYL3
   • No demonstration that human SCYL3 binds COPI subunits
   • Link between COPI function and the migration/neuronal roles untested
4. 2022 Medium

   Identified ROCK2 as a direct C-terminal binding partner that SCYL3 stabilizes, connecting SCYL3 to Rho-kinase signaling, actin remodeling, and tumor cell migration/metastasis.

   Evidence Reciprocal co-immunoprecipitation, knockdown/overexpression in HCC cells, and an in vivo mouse metastasis model

   PMID:36440258

   Open questions at the time

   • Mechanism by which SCYL3 stabilizes ROCK2 not defined
   • Single lab; not independently confirmed
   • Relationship between ROCK2 binding and ezrin/Golgi localization not integrated

• How SCYL3's scaffolding at the Golgi and cytoskeleton mechanistically connects to ROCK2 signaling and to SCYL1-redundant TDP-43 proteostasis remains unresolved.
• No unified mechanism linking trafficking, cytoskeletal, and neuronal functions
• No structural model of SCYL3 domains in complex with partners
• Identity of the 'associated' kinase activity remains unknown